11 Things Doctors Still Get Wrong About Menopause
The number of women who've been handed an antidepressant prescription or told 'your bloods are normal' when they were clearly in perimenopause is honestly staggering — and heartbreaking. It took years for many of them to piece together what was actually happening to their bodies, often through their own research rather than medical support. Nobody should have to fight this hard to be taken seriously about their own hormones.
Learn more about Rose →"Your blood test is normal, so it isn't menopause"
FSH and oestradiol levels fluctuate dramatically during perimenopause, sometimes day to day, which means a single normal result can be genuinely meaningless. Clinical guidelines from bodies including the British Menopause Society explicitly state that perimenopause is a clinical diagnosis in women over 45 — symptoms and age should guide assessment, not a single hormone snapshot. Relying solely on bloodwork causes significant diagnostic delays, particularly for women in their early-to-mid forties.
Treating hot flushes as the only real symptom
Hot flushes are the symptom most associated with menopause in public and clinical consciousness, but the hormonal transition can produce more than 30 recognised symptoms including anxiety, joint pain, itchy skin, heart palpitations, and urinary urgency. When clinicians focus exclusively on vasomotor symptoms, women presenting with less-familiar complaints are routinely misdiagnosed or dismissed. A fuller understanding of the symptom spectrum is essential to accurate, timely care.
Conflating perimenopause with menopause
Menopause is technically a single moment — 12 consecutive months without a period — while perimenopause is the transitional phase that can precede it by up to a decade. Many clinicians use the two terms interchangeably, which matters because symptoms during perimenopause can be intense and destabilising long before periods actually stop. Women in their late thirties and forties are sometimes told they "aren't menopausal yet" when they are already deep into hormonal transition.
Overstating the breast cancer risk of HRT
Much of the fear around hormone replacement therapy traces back to a widely misreported 2002 Women's Health Initiative study, whose absolute risk increases were small and whose methodology has since been substantially criticised. Current evidence indicates that for most women under 60 who are within ten years of menopause, the benefits of HRT outweigh the risks, and certain types — particularly transdermal oestrogen with micronised progesterone — carry a much more favourable risk profile than older oral combined preparations. Many women are still being refused or discouraged from HRT based on a risk calculation that is no longer considered accurate.
Prescribing antidepressants as a first-line response to mood changes
Low mood, irritability, anxiety, and emotional dysregulation during perimenopause are often driven by fluctuating oestrogen acting on serotonin and GABA pathways — a physiological process, not a primary depressive disorder. While antidepressants have a role in some cases, offering them as the default response before considering hormonal causes means the underlying driver goes unaddressed. Research consistently shows that oestrogen therapy can be highly effective for mood symptoms in perimenopausal women, yet it remains underprescribed relative to antidepressants for this population.
Dismissing genitourinary symptoms as minor or inevitable
Genitourinary Syndrome of Menopause — which encompasses vaginal dryness, thinning, pain during sex, and urinary symptoms — affects an estimated 50 to 60 percent of postmenopausal women, yet remains severely undertreated because many clinicians do not raise it and many women feel too embarrassed to. Unlike hot flushes, which often improve over time, genitourinary symptoms tend to worsen without treatment and can significantly impact quality of life and intimate relationships. Topical vaginal oestrogen is highly effective, carries minimal systemic absorption, and can be used safely by the vast majority of women.
Assuming 51 is the expected age and treating earlier symptoms as unrelated
The average age of menopause in the UK and US is around 51, but perimenopause commonly begins in the mid-to-late forties — and for some women, meaningful hormonal changes begin in their late thirties. Women presenting with classic symptoms at 42 or 44 are frequently told they are "too young" and sent away without investigation. This error is particularly damaging because early identification allows for earlier intervention, including bone and cardiovascular protection.
Overlooking cognitive symptoms as a sign of serious neurological disease
Brain fog, word-finding difficulties, and short-term memory lapses are among the most frightening symptoms of perimenopause and are frequently catastrophised — or dismissed — rather than correctly attributed to oestrogen fluctuation. Oestrogen plays a well-documented role in neurological function, synaptic plasticity, and cerebral blood flow, which explains why cognitive symptoms can appear alongside other hormonal changes. Women deserve to be told that these symptoms are common, well understood physiologically, and typically improve with hormonal stabilisation.
Underestimating the cardiovascular implications of menopause
Oestrogen has significant cardioprotective effects on lipid profiles, arterial flexibility, and inflammatory markers — effects that diminish after menopause and contribute to a measurable increase in cardiovascular disease risk in postmenopausal women. Despite heart disease being the leading cause of death in women over 60, many clinicians do not connect the menopause transition with cardiovascular risk in the way they would with other major life-stage changes. HRT initiated early in the transition (the so-called "timing hypothesis") may confer cardiovascular benefit, though this remains an active area of research.
Failing to address bone density until it is already a problem
Bone density loss accelerates sharply in the first five to ten years after menopause due to the withdrawal of oestrogen, which normally suppresses the activity of bone-resorbing osteoclasts. Many women are not warned about this until a fracture occurs or a DEXA scan shows established osteopenia or osteoporosis — a point at which significant, irreversible bone loss has already happened. Proactive conversation about bone health, calcium and vitamin D status, weight-bearing exercise, and the role of HRT in bone preservation should be part of standard menopause care.
Treating menopause as a short-term event rather than a long-term health transition
A woman who reaches menopause at 51 may live for another 35 or 40 years in a post-menopausal state — yet menopause is often framed clinically as a brief, uncomfortable episode that women simply need to get through. The downstream effects on bone, cardiovascular health, cognitive function, metabolic health, and sexual wellbeing require long-term, proactive management rather than a symptom-by-symptom reactive approach. Women benefit enormously when clinicians treat the menopause transition as a pivotal window for preventive health intervention, not just a complaints triage.
Want to go deeper?
Rose covers every symptom, supplement, and condition in full detail — evidence-graded and agenda-free.
Rose is a free, evidence-based reference built for women navigating perimenopause and menopause. No ads. No products to sell. No agenda. Just honest answers — because every woman in this season deserves a trusted friend who has done the research.